Cargando…

A "prime-pull" immunotherapy approach using a lentiviral vector and intratumoral TLR4 agonist redirects cytotoxic T cells

Detalles Bibliográficos
Autores principales:	Albershardt, Tina C, Parsons, Andrea J, Flynn, Patrick, Berglund, Peter, ter Meulen, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292388/ http://dx.doi.org/10.1186/2051-1426-2-S3-P190

Ejemplares similares

Intratumoral injections of G100 (synthetic TLR4 agonist) increase trafficking of lentiviral vector-induced antigen-specific CD8 T cells to the tumor microenvironment
por: Albershardt, Tina C, et al.
Publicado: (2015)

Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory
por: Leleux, Jardin A., et al.
Publicado: (2021)

Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors
por: Albershardt, Tina C., et al.
Publicado: (2020)

Checkpoint inhibitors synergize with therapeutic platforms, ZVex™ and GLAAS™ by enhancing lentiviral vector-induced tumor-specific immunity and adjuvant-mediated anti-tumor efficacy
por: Albershardt, Tina C, et al.
Publicado: (2015)

LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response
por: Albershardt, Tina Chang, et al.
Publicado: (2016)

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
por: Smirnov, DV, et al.
Publicado: (2013)

Toll-Like Receptor 4 Expression on Lymphoma Cells Is Critical for Therapeutic Activity of Intratumoral Therapy With Synthetic TLR4 Agonist Glucopyranosyl Lipid A
por: Lu, Hailing, et al.
Publicado: (2020)

Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy
por: Boss, Mary-Keara, et al.
Publicado: (2022)

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
por: Mullins, Stefanie R., et al.
Publicado: (2019)

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
por: Fromm, George, et al.
Publicado: (2018)

Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Huckaby, Justin T, et al.
Publicado: (2021)

Virological and Preclinical Characterization of a Dendritic Cell Targeting, Integration-deficient Lentiviral Vector for Cancer Immunotherapy
por: Odegard, Jared M., et al.
Publicado: (2015)

Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies
por: Parker, Christina L., et al.
Publicado: (2020)

Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists
por: Andón, Fernando Torres, et al.
Publicado: (2022)

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
por: Lee, Won Suk, et al.
Publicado: (2022)

Redirecting the focus of cancer immunotherapy to premalignant conditions
por: Young, M. Rita I.
Publicado: (2017)

Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2020)

Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer
por: Dorff, Tanya B., et al.
Publicado: (2022)

Differential Response of Gestational Tissues to TLR3 Viral Priming Prior to Exposure to Bacterial TLR2 and TLR2/6 Agonists
por: Rasheed, Zahirrah B. M., et al.
Publicado: (2020)

HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells
por: Wee, Edmund G., et al.
Publicado: (2017)

Intratumoral Immunotherapy—Update 2019
por: Hamid, Omid, et al.
Publicado: (2019)

Trial watch: intratumoral immunotherapy
por: Humeau, Juliette, et al.
Publicado: (2021)

Immunotherapeutic Agents for Intratumoral Immunotherapy
por: Shyr, Chih-Rong, et al.
Publicado: (2023)

Correction to: Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2021)

The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma
por: Zhou, Zhimei, et al.
Publicado: (2021)

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
por: Märkl, Florian, et al.
Publicado: (2023)

Lentiviral Vectors for Cancer Immunotherapy and Clinical Applications
por: Liechtenstein, Therese, et al.
Publicado: (2013)

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
por: Younes, Ahmed I., et al.
Publicado: (2020)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

Intratumoral TNFα improves immunotherapy
por: Johansson, Anna, et al.
Publicado: (2012)

Characterization of intratumor microbiome in cancer immunotherapy
por: Zhang, Zhao, et al.
Publicado: (2023)

Tregs constrain CD8(+) T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapy
por: Palmeri, Joseph R., et al.
Publicado: (2023)

Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

Redirecting host preexisting influenza A virus immunity for cancer immunotherapy
por: Chaganty, Bharat K. R., et al.
Publicado: (2021)

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
por: Lussana, Federico, et al.
Publicado: (2021)

Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine
por: Tran, Christine A, et al.
Publicado: (2023)

Successful application of prime and pull strategy for a therapeutic HSV vaccine
por: Bernstein, David I., et al.
Publicado: (2019)

TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects
por: Lu, Hailing
Publicado: (2014)

Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma
por: Deng, Shuanglin, et al.
Publicado: (2014)

Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy
por: Rodell, Christopher B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cnsob9jauvosks18e4rckpshfb